Citigroup analyst Ashwin Shirvaikar upgrades The Western Union (NYSE:WU) from Neutral to Buy.
Beam Therapeutics Outlined Long-term Strategy for Base Editing Programs in Sickle Cell Disease and Provided Preclinical Data Updates at ASH 2021
Beam Therapeutics Inc. (NASDAQ: BEAM), a biotechnology company developing precision genetic medicines through base editing, today shared a three-stage, long-term development strategy for its base editing approach to treat sickle cell disease (SCD).
